New therapies for castrate-resistant prostate cancer

被引：3

作者：

Williams, Stephen B. ^{[1
]}

Lay, Aaron H. ^{[1
]}

Lau, Clayton S. ^{[2
]}

Josephson, David Y. ^{[2
]}

Wilson, Timothy G. ^{[2
]}

Choueiri, Toni K. ^{[3
]}

Pal, Sumanta K. ^{[4
]}

机构：

[1] Harvard Univ, Brigham & Womens Hosp, Div Urol, Sch Med, Boston, MA 02115 USA

[2] City Hope Comprehens Canc Ctr, Div Urol Oncol, Dept Urol, Duarte, CA 91010 USA

[3] Harvard Univ, Lank Ctr Genitourinary Oncol, Dana Farber Canc Inst, Sch Med, Boston, MA 02115 USA

[4] City Hope Comprehens Canc Ctr, Div Genitourinary Malignancies, Dept Med Oncol & Expt Therapeut, Duarte, CA 91010 USA

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2011年 / 12卷 / 13期

关键词：

castrate resistant; chemotherapy; outcomes; prostate cancer; review; MITOXANTRONE PLUS PREDNISONE; I CLINICAL-TRIAL; ABIRATERONE ACETATE; ANTITUMOR-ACTIVITY; DOCETAXEL; CYP17; INHIBITOR; IMMUNOTHERAPY; ANTIANDROGEN; CHEMOTHERAPY;

D O I：

10.1517/14656566.2011.590133

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Prostate cancer is the second leading cause of cancer death in men in the USA, and most of these deaths will occur as a result of castrate-resistant prostate cancer (CRPC) that has progressed despite androgen deprivation therapy. There has been better understanding of castration resistance and molecular mechanisms of prostate cancer progression recently, leading to new treatment strategies. Areas covered: This review focuses on emerging and new therapies for castrate-resistant prostate cancer, including hormonal therapy, immunotherapy and cytotoxic agents. Expert opinion: New treatment strategies have been developed in recent years and, with improved understanding of advanced CRPC, additional targeted treatments are expected in the near future. Further cost effectiveness research of these treatments is warranted before dissemination of these promising agents.

引用

页码：2069 / 2074

页数：6

共 50 条

[21] Metastatic castrate-resistant prostate cancer: New landscape, new challenges
Bahl, Amit
Persad, Raj
[J]. JOURNAL OF CLINICAL UROLOGY, 2011, 4 (01) : S9 - S13
[22] Current management of castrate-resistant prostate cancer
Hotte, S. J.
Saad, F.
[J]. CURRENT ONCOLOGY, 2010, 17 : S72 - S79
[23] Palliative Care in Castrate-Resistant Prostate Cancer
Rabow, Michael W.
Lee, Michael Xiang
[J]. UROLOGIC CLINICS OF NORTH AMERICA, 2012, 39 (04) : 491 - +
[24] Expanding the Armamentarium for Castrate-resistant Prostate Cancer
Waugh, David J. J.
[J]. EUROPEAN UROLOGY, 2017, 71 (03) : 328 - 329
[25] Olaparib in metastatic castrate-resistant prostate cancer
不详
[J]. BJU INTERNATIONAL, 2020, 126 (02) : 235 - 235
[26] Molecular Mechanisms of Castrate-Resistant Prostate Cancer
Kotamarti, Srinath
Armstrong, Andrew J.
Polascik, Thomas J.
Moul, Judd W.
[J]. UROLOGIC CLINICS OF NORTH AMERICA, 2022, 49 (04) : 615 - 626
[27] Update on castrate-resistant prostate cancer: 2010
Lassi, Kiran
Dawson, Nancy A.
[J]. CURRENT OPINION IN ONCOLOGY, 2010, 22 (03) : 263 - 267
[28] Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Karnes, R. Jeffrey
Ahmed, Mohamed E.
[J]. APPLIED RADIOLOGY, 2021, 50 (01) : 42 - 43
[29] Castrate-resistant prostate cancer: the future of antiandrogens
Pchejetski, Dmitri
Alshaker, Heba
Stebbing, Justin
[J]. TRENDS IN UROLOGY & MENS HEALTH, 2014, 5 (01) : 7 - 10
[30] Guidelines for the management of castrate-resistant prostate cancer
Saad, Fred
Hotte, Sebastien J.
[J]. CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2010, 4 (06): : 380 - 384

← 1 2 3 4 5 →